secwatch.observer — SEC 8-K summary
======================================

Issuer:     VACCINEX, INC. (VCNX)
CIK:        0001205922
Form:       8-K
Filed at:   2022-11-10T23:59:59+00:00
Accession:  0001193125-22-282054
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vaccinex reports 100% recurrence-free at 24 months in Stage III melanoma triple combination
--------------------------------------------------------------------------------

- Triple combo (pepinemab+nivolumab+ipilimumab) achieved 100% recurrence-free survival at 24 months vs <40% for dual combos.
- LAG-3 upregulation identified as resistance mechanism to pepinemab+nivolumab; rationale for triple with LAG-3 inhibitor.
- Pepinemab combinations induced tertiary lymphoid structures and CD26hi CD4+ T cells in tumors.
- Phase 1/2 trial enrolling for pepinemab+trastuzumab+DC vaccine in HER2+ metastatic breast cancer (NCT05378464).
- Interim analysis of KEYNOTE-B84 (pepinemab+KEYTRUDA in HNSCC) expected in Q1 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1205922/000119312522282054/0001193125-22-282054-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1205922/000119312522282054/d408251d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-282054

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer